In a multicenter case-control study, the GALAD score’s ability to diagnose HCC was confirmed even in NASH patients, with a significantly higher AUROC than serum AFP, AFP-L3, or DCP alone (96% vs. 88%, 86%, and 87%, respectively). Here, AFP is linked to hepatocellular carcinoma.